Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group.
Andrea J MacNeill, Alessandro Gronchi, Rosalba Miceli...
https://pubmed.ncbi.nlm.nih.gov/28394870/Actively Recruiting
Led by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Updated on 2019-02-12
2000
Participants Needed
22
Research Sites
521 weeks
Total Duration
Researchers are conducting a prospective observational study to collect standardized clinical, radiological, and pathological data from patients with primary retroperitoneal sarcoma RPS treated with surgery at specialized centers. This study aims to evaluate patient outcomes such as overall survival, disease-free survival, local recurrence, and distant metastasis. RPS is a rare type of tumor located in the retroperitoneal space, with several histological subtypes that influence prognosis and treatment responses. Eligible patients undergo surgical treatment according to current standards, with data collected on tumor characteristics, treatments, and follow-up findings. Radiological exams like contrast-enhanced CT or MRI scans are performed before surgery. The study tracks the use and impact of multimodal therapies including surgery, radiation, and chemotherapy. Follow-up includes clinical evaluation and imaging every 4 months for the first 2 years, every 6 months until year 5, and yearly thereafter. Data and pathological samples are stored at participating centers and shared in a deidentified manner to maintain confidentiality. Participants provide informed consent and are monitored over time with scheduled visits and imaging to assess disease status and treatment effects. Researchers measure outcomes including 10-year disease-free survival, overall survival, and incidence of local recurrence and distant metastasis. Patient compliance with follow-up is required. The study is ongoing with no fixed end date and aims to include approximately 400 patients per year, contributing to high-quality prospective data on this rare disease.
CONDITIONS
REtroperitoneal SArcoma Registry: an International Prospective Initiative
A
Alessandro Gronchi, MD
M
Marco Fiore, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead Sponsor
TransAtlantic Retroperitoneal Sarcoma Working Group
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Not specified
Participants undergo surgery for primary retroperitoneal sarcoma and receive immediate post-operative care.
1 surgical procedure and immediate hospital stay
Duration - Up to 10 years
Participants are followed up with clinical evaluation and imaging to monitor disease status and detect any recurrence or metastasis.
Visits every 4 months for 2 years, every 6 months until 5 years, then yearly visits thereafter
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Andrea J MacNeill, Alessandro Gronchi, Rosalba Miceli...
https://pubmed.ncbi.nlm.nih.gov/28394870/Mengmeng Xiao, Xiangji Li, Fanqin Bu...
https://pubmed.ncbi.nlm.nih.gov/40407808/Yu Zhao, Da Qin, Xiangji Li...
https://pubmed.ncbi.nlm.nih.gov/38733554/Trans-Atlantic RPS Working Group
https://pubmed.ncbi.nlm.nih.gov/25316486/Laura Benuzzi, Sara Iadecola, Marco Fiore...
https://pubmed.ncbi.nlm.nih.gov/41176815/Alessandro Gronchi, Dirk C Strauss, Rosalba Miceli...
https://pubmed.ncbi.nlm.nih.gov/26727100/Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead Sponsor
TransAtlantic Retroperitoneal Sarcoma Working Group
Collaborating Sponsor